C1qScreen - 補体結合性HLA抗体検出試薬

LABScreen検出試薬 (PE Conjugated Goat Anti-Human IgG、商品コード:LS-AB2) の代わりにC1qScreenを使用することで、補体結合性のHLA抗体を特異的に検出します。通常のLABScreenデータとの比較解析から、反応したHLA抗体が補体結合性であるかどうかを観察することが可能になります。



? C1q 、25 μL (1 μL/test)
? PE-labeled anti-C1q 、125 μL (5 μL/test)
? C1q positive control beads 、12.5 μL (0.5 μL/test)
? HEPES buffer (10 mM HEPES pH 7.2)、100μL (4 μL/test)

? PBS、 pH 7.4 ( Ca++なし 、または Mg++なし)
? LABScreen各種製品
? 96ウェルマイクロプレート(Whatman Cat. # 7701-3250 または同等品)
? トレーシール (カタログ番号:SSPSEA300 または同等品)
? C1q Screen Positive Control Class I (カタログ番号: C1QS-PC1)
? C1q Screen Positive Control Class II(カタログ番号:C1QS-PC2)
・C1q Screen Negative Control (カタログ番号:C1QS-NC)

  ● お手持ちのLABScreenビーズにサンプル血清を添加する前にC1qと反応させ、PE標識抗C1q抗体で検出することで補体結合性のHLA抗体を特異的に測定します。
  ● LABScan 100 (Luminex) によるデータ読取方法は、通常のLABScreenと同様です。

* 通常のLABScreenとは操作方法が異なりますので、ご注意ください。
  1) サンプル血清の非働化 (56℃, 30分)
  2) C1qストック溶液をHEPESバッファーで希釈
  3) 非働化したサンプル血清、希釈したC1q溶液を混合
  4) LABScreenビーズを添加し、室温で20分間インキュベート
  5) PE標識抗C1q抗体を添加し、室温で20分間インキュベート
  6) 洗浄
  7) LABScan 100で検出、専用判定ソフトで判定

● One Lambda社ニュースレター (2010年春号・英語)

■関連文献 (要旨) リンク■
● 腎臓移植後の患者生検/血清を用いた、補体結合性HLA抗体のモニタリング
   Yabu JM, et al. Transplantation. 2011 Feb 15; 91(3): 342-7.

● 心臓移植後の患者血清を用いた、補体結合性HLA抗体の検出例
   Chin C, et al. J Heart Lung Transplant. 2011 Feb; 30(2): 158-63.





LABScreen Single Antigen


LABScreen Mixed

LABScreen Multi

LABScan 100

LABScreen 専用試薬


One Lambda社 製品情報




HLA Fusion解析用ファイル


製品コード 製品名 梱包単位 保存温度 該当法規 MSDS マニュアル・関連資料
日本語 英語 その他
C1Q C1qScreen 25tests 超冷凍(-80℃)  
C1QS-NC C1qScreen Negative Control Serum 100uL 超冷凍(-80℃)  
C1QS-PC1 C1qScreen Class I Positive Control 100uL(20tests) 超冷凍(-80℃)  
C1QS-PC2 C1qScreen Class II Positive Control 100uL(20tests) 超冷凍(-80℃)  



Reference List

Thammanichanond, D., Mongkolsuk T, Rattanasiri S, et al. Significance of C1q-fixing Donor-Specific Antibodies After Kidney Transplantation. Transplant Proc, 2014;46(2):368?71. Kheradmand, T., Anthony TL, Harland RC, et al. Antibody-mediated rejection in ABO compatible husband to wife living donor liver transplant and review of the literature. Hum Immunol. 2014. Kubal CA, Mangus RS, Saxena R, et al. Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction. Transplantation. 2014;97(1):56?63. Crespo M, Torio A, Mas V, et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Transpl Immunol. 2013;29(1-4):28?33. Duquesnoy RJ, Marrari M, Jelenik L, Zeevi A, Claas FHJ, Mulder A. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays. Hum Immunol. 2013;74(10):1271-9. Freitas MCS, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013;95(9):1113-9. Guidicelli G, Anies G, Bachelet T, et al. The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients. Transpl Immunol. 2013;29(1-4):17-21. Iyer HS, Jackson AM, Zachary AA, Montgomery RA. Transplanting the highly sensitized patient: trials and tribulations. Curr Opin Nephrol Hypertens. 2013;22(6):681-8. Lawrence C, Willicombe M, Brookes P a, et al. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Transplantation. 2013;95(2):341-6. Leonard GR, Shike H, Uemura T, et al. Liver transplantation with a strongly positive crossmatch: case study and literature review. Liver Transpl2013;19(9):1001-10. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369(13):1215-26. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation2013;95(1):19-47. Tinckam KJ, Heeger PS. Transplantation: Complementing donor-specific antibody testing. Nat Rev Nephrol. 2013;9(12):713-4. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2013;32(1):98-105. AlMahri a, Holgersson J, Alheim M. Detection of complement-fixing and non-fixing antibodies specific for endothelial precursor cells and lymphocytes using flow cytometry. Tissue Antigens. 2012;80(5):404-15. Berger M, Zeevi A, Farmer DG, Abu-Elmagd KM. Immunologic challenges in small bowel transplantation. Am J Transplant. 2012;12 Suppl 4:S2-8. Biglarnia A-R, Nilsson B, Nilsson Ekdahl K, et al. Desensitization with antigen-specific immunoadsorption interferes with complement in ABO-incompatible kidney transplantation. Transplantation. 2012;93(1):87-92. Chang D, Kobashigawa J. The use of the calculated panel-reactive antibody and virtual crossmatch in heart transplantation. Curr Opin Organ Transplant. 2012;17(4):423-6. Debiec H, Hanoy M, Francois A, et al. Recurrent membranous nephropathy in an allograft caused by IgG3κ targeting the PLA2 receptor. J Am Soc Nephrol. 2012;23(12):1949-54. Galvan MD, Greenlee-Wacker MC, Bohlson SS. C1q and phagocytosis: the perfect complement to a good meal. J Leukoc Biol. 2012;92(3):489-97. Jordan SC. Complement fixing donor-specific antibodies and allograft loss. Pediatr Transplant. 2012;16(1):1-3. Kokko KE, Colvin RB. Below the waterline ? the danger of de novo donor-specific HLA antibodies. Am J Transplant. 2012;12(5):1077-8. Llorente S, Boix F, Eguia J, et al. C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG. Transplant Proc. 2012;44(9):2535-7. Murphey CL, Bingaman AW. Histocompatibility considerations for kidney paired donor exchange programs. Curr Opin Organ Transplant. 2012;17(4):427-32. Otten HG, Verhaar MC, Borst HPE, Hene RJ, van Zuilen a D. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant. 2012;12(6):1618-23. Reinsmoen NL. New approaches for optimizing transplant of sensitized patients. Curr Opin Organ Transplant. 2012;17(4):406-8. Sutherland SM, Chen G, Sequeira F a, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2012;16(1):12-7. Takenaka M, Subramanian V, Tiriveedhi V, et al. Complement activation is not required for obliterative airway disease induced by antibodies to major histocompatibility complex class I: Implications for chronic lung rejection. J Heart Lung Transplant. 2012;31(11):1214-22.. Tyan DB. New approaches for detecting complement-fixing antibodies. Curr Opin Organ Transplant. 2012;17(4):409-15. Zeevi A, Lunz J. HLA antibody profiling in thoracic transplantation undergoing desensitization therapy. Curr Opin Organ Transplant. 2012;17(4):416-22. Zeevi A, Marrari M, Feingold B, Webber S, Duquesnoy RJ. Human leukocyte antigen epitope analysis to assess complement- and non-complement-binding donor-specific antibody repertoire in a pediatric heart transplant recipient Hum Immunol. 2012;73(1):48-51.


必要に応じて順次回答させていただきますが、お急ぎの場合はこちらより直接お電話にてお問い合わせください。  *必須

お名前* 姓:   名: お問合せ内容*


CAPTCHA Image 文字を入力 [ 画像を変更する ]